| Active, not recruiting |
: MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
: - Ovarian Carcinoma
- Fallopian Tube Cancer
- Peritoneal Cancer<
: 2010-03-17
: - Drug: MLN8237 + Paclitaxel
|
| Terminated |
: Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
: - Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
: 2010-03-01
:
|
| Active, not recruiting |
: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
: - Cognitive Side Effects of Cancer Therapy
- Malignant Ovarian Epithelial Tumor
-
- Procedure: Cognitive Assessment
|
| Active, not recruiting |
: Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
: - Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Can
: 2010-02-23
: - Genetic: gene expression analysis
- Genetic:
|
| Completed |
: LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
: - Ovarian Neoplasms
- Peritoneal Neoplasms
: 2009-11-09
: - Drug: Placebo comparator to BI
|
| Active, not recruiting |
: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
: - Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
-
- Biological: Bevacizumab Given
|
| Completed |
: Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
: - Fallopian Tube Cancer
- Metastatic Cancer
- Ovarian Cancer
: 2009-10-09
: - Drug: carboplatin Carboplatin
|
| Active, not recruiting |
: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
-
- Biological: Bevacizumab Given
|
| Completed |
: Study of Paclitaxel in Patients With Ovarian Cancer
: - Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallop
: 2009-09-28
:
|
| Completed |
: Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Ca
: 2009-08-12
: - Other: communication intervention
- Other: e
|
